相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)
Mohammad Shafi Kuchay et al.
DIABETES CARE (2018)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Randomized, 24-Week, Open-Label, Active-Controlled Trial
Daisuke Ito et al.
DIABETES CARE (2017)
A comparison of low volume 'high-intensity-training' and high volume traditional resistance training methods on muscular performance, body composition, and subjective assessments of training
J. Giessing et al.
BIOLOGY OF SPORT (2016)
Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors
Takamasa Ohki et al.
CLINICAL DRUG INVESTIGATION (2016)
Effect of canagliflozin on liver function tests in patients with type 2 diabetes
L. A. Leiter et al.
DIABETES & METABOLISM (2016)
SGLT2 inhibitors provide an effective therapeutic option for diabetes complicated with insulin antibodies
Akinori Hayashi et al.
ENDOCRINE JOURNAL (2016)
Body composition in overweight and obese women postpartum: bioimpedance methods validated by dual energy X-ray absorptiometry and doubly labeled water
L. Ellegard et al.
EUROPEAN JOURNAL OF CLINICAL NUTRITION (2016)
Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography
Kento Imajo et al.
GASTROENTEROLOGY (2016)
Non-alcoholic fatty liver disease and diabetes
Jonathan M. Hazlehurst et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2016)
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Christoph Wanner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes
Teruo Jojima et al.
DIABETOLOGY & METABOLIC SYNDROME (2016)
Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition
Giulia Ferrannini et al.
DIABETES CARE (2015)
Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient L-amino acid-defined diet in rats
Yuka Hayashizaki-Someya et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2015)
Nonalcoholic Fatty Liver Disease A Systematic Review
Mary E. Rinella
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
SGLT2 inhibitors in the treatment of type 2 diabetes
Farhad M. Hasan et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2014)
SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats
Masanori Yokono et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2014)
Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats
Atsuo Tahara et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2014)
MR Imaging of Diffuse Liver Disease From Technique to Diagnosis
Thomas A. Hope et al.
RADIOLOGIC CLINICS OF NORTH AMERICA (2014)
The presentation of metabolic dysfunction and the relationship with energy output in breast cancer survivors: a cross-sectional study
Emer M. Guinan et al.
NUTRITION JOURNAL (2013)
Non-Alcoholic Fatty Liver Disease (NAFLD) and Its Connection with Insulin Resistance, Dyslipidemia, Atherosclerosis and Coronary Heart Disease
Melania Gaggini et al.
NUTRIENTS (2013)
Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials
G. Musso et al.
DIABETOLOGIA (2012)
A comparison of dual energy X-ray absorptiometry and bioelectrical impedance analysis to measure total and segmental body composition in healthy young adults
Siobhan Leahy et al.
EUROPEAN JOURNAL OF APPLIED PHYSIOLOGY (2012)
Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin
Jan Bolinder et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Why Does NAFLD Predict Type 2 Diabetes?
Guido Lattuada et al.
CURRENT DIABETES REPORTS (2011)
Prevalence of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among a Largely Middle-Aged Population Utilizing Ultrasound and Liver Biopsy: A Prospective Study
Christopher D. Williams et al.
GASTROENTEROLOGY (2011)
Comparison of Noninvasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
Amy G. Shah et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2009)
Quantification of Hepatic Steatosis With MRI: The Effects of Accurate Fat Spectral Modeling
Scott B. Reeder et al.
JOURNAL OF MAGNETIC RESONANCE IMAGING (2009)
Effects of diet-induced moderate weight reduction on intrahepatic and intramyocellular triglycerides and glucose metabolism in obese subjects
Fumihiko Sato et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD
Paul Angulo et al.
HEPATOLOGY (2007)
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection
Richard K. Sterling et al.
HEPATOLOGY (2006)
Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference
BA Neuschwander-Tetri et al.
HEPATOLOGY (2003)
分享论文
